Rotavirus Infections Clinical Trial
Official title:
Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study of the Safety and Efficacy of the Vaccine for the Prevention of Pentavalent Live Rotavirus Infection in Healthy Subjects (Target Age of 18-45 Years Old).
Verified date | August 2021 |
Source | Limited Liability Company Pharm Aid |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the presented study was to evaluate the safety and immunological efficacy in preventing the rotavirus infection within a cohort of healthy subjects (target age of 18-45 years old) by using the pentavalent rotavirus vaccine - Rota-V-Aid™ (live attenuated oral, freeze-dried).
Status | Completed |
Enrollment | 40 |
Est. completion date | July 27, 2018 |
Est. primary completion date | July 27, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. The signed informed consent; 2. Healthy participants, men's and females aged from 18 up to 45 years inclusive; 3. Readiness of participants and their sexual partners to use reliable methods of contraception (a combination of at least two modes, including one barrier method, for example, use of a spermicide and condom) from the moment of signing of the informed consent (that is in 3 days before administration of drugs) and before the expiration of 1 month after completion of participation in the study; 4. The verified diagnosis "is healthy," established according to collecting the anamnesis and physical inspection: - absence in the anamnesis and at the time of screening clinically significant dysfunctions cardiovascular, respiratory, nervous, hemopoietic, endocrine, gastrointestinal systems, liver, and kidneys; - absence of persistent infections (HIV, hepatitis B, C, syphilis); - absence within 30 days before inclusion in the study of sharp, infectious diseases; - absence of the mental disorders and any other states capable to affectability of the participant to follow requirements of the protocol; - lack of complaints to the state of health within 30 days before inclusion in the study; - hemodynamic indicators within norm: systolic arterial blood pressure - within 100 - 130 mm Hg., diastolic arterial blood pressure - within 60 - 90 mm Hg; 5. The Body Mass Index (BMI) is in normal limits (=18.5 kg/sq.m and =30 kg/sq.m); 6. There is a lack of instructions on alcohol abuse or narcotic dependence at the time of inclusion in study or the anamnesis; 7. The participant's Ability, according to the study, to fulfill the requirements of the protocol. Exclusion Criteria: 1. The severe vaccine-challenged reactions/complications connected with the previous vaccination; 2. Allergic reactions to components of vaccine or any previous vaccination; 3. Any carried-out vaccination less than in 2 months before the present study; 4. In the chronic anamnesis diseases of the digestive tract, causes intestinal invagination, gastrointestinal pathology, surgical interventions on abdominal organs; 5. Clinically significant deviations of laboratory and tool indicators (including standard pathological changes on the ECG) overstepping the bounds of the range of normal values revealed on screening and capable of negatively impacting the safety of participants of the volunteer in the study; 6. Any diseases within four weeks preceding screening; 7. Presence of any oncological diseases (including in the anamnesis); 8. Any disease demands continuous therapy, including vegetable drugs or the expected concurrent therapy during the study; 9. Donor blood donation (450 ml of blood or plasma and more) or loss of 500 or more ml of blood in 3 months before the study; 10. Positive analysis on HIV, Hepatitis B and C, and syphilis (RW); 11. Impossibility to give the written informed consent or to follow requirements of the protocol; 12. Probability to refuse to follow the protocol's requirements, instructions and restrictions; for example, unwillingness to cooperate, impossibility to return to clinical center for the subsequent visits, and the probability not of completion of participation in a clinical trial; 13. Participation in clinical trials of drugs less than in 3 months before the study; 14. Smoking more than ten cigarettes in a day; 15. Drug addiction in the anamnesis. The positive analysis of urine on psychotropic and narcotic substances, psychoactive medicines; 16. Regular alcohol intake in many ?10 units a week (to 1 unit of alcohol is equivalent to ½ l of beer, 200 ml of wine, or 50 ml of hard liquors) or anamnestic data on alcoholism. Alcohol intake within 48 hours before the Screening visit. Positive respiratory test for alcohol on screening (breathalyzer); 17. Observance of a special diet (for example, vegetarian, observance of a post, etc.) or lifestyle (including work at night and extreme physical activities, such as sport or raising of weights) which can interfere with carrying out the study; 18. The study cannot include military personnel or employees law enforcement agencies serving sentences in places of detention or being in custody; 19. The presence of conviction of the study is that the volunteer will not follow procedures of the protocol; 20. Use of any medicines, including OTC, vegetable medicines, dietary supplements, within 14 days before the study, according to the study. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Perm State Medical University named after Academician E.A. Wagner | Perm |
Lead Sponsor | Collaborator |
---|---|
Limited Liability Company Pharm Aid |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Geometric Mean Titer (GMT) of antibody | 28 days post-Dose 1 | ||
Primary | Seroconversion level | 28 days after Dose 1 of vaccine | ||
Primary | Seroconversion factor (The increase in the geometric mean antibody titer on day 28 compared to the initial level is expressed in the fold increase.). | The seroconversion factor after administration of the study vaccine was 1.20, after administration of placebo - 0.97. | 28 days post-Dose 1 | |
Primary | Frequency and expressiveness of AE /SAE. | From the time of Dose 1 to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
Completed |
NCT02220439 -
Does the Fecal Microbiome Influence Rotarix Immunogenicity
|
N/A | |
Withdrawn |
NCT00757926 -
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT00484952 -
Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel
|
N/A | |
Completed |
NCT00092443 -
Dose Confirmation Efficacy Study (V260-007)
|
Phase 3 | |
Terminated |
NCT01357174 -
ROTATEQ™ Post-Marketing Surveillance in the Philippines
|
N/A | |
Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT06080906 -
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
|
Phase 2 | |
Recruiting |
NCT03313128 -
SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance
|
||
Completed |
NCT02542462 -
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
|
Phase 4 | |
Completed |
NCT00346892 -
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV
|
Phase 2 | |
Not yet recruiting |
NCT05212935 -
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
|
||
Completed |
NCT00092456 -
Consistency Lots Vaccine Study (V260-009)
|
Phase 3 | |
Completed |
NCT00981669 -
Rotavirus Vaccine Produced by Butantan Institute
|
Phase 1 | |
Completed |
NCT03483116 -
A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine
|
Phase 2 | |
Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A | |
Active, not recruiting |
NCT05621655 -
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
|
Phase 2 | |
Completed |
NCT00280111 -
Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants
|
Phase 1 | |
Completed |
NCT00090233 -
Rotavirus Efficacy and Safety Trial (REST)(V260-006)
|
Phase 3 |